Aktieselskabet Schouw & Co. (LON:0O0N)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 1.74B +11.3% |
| Revenue (ttm) | 3.96B -2.3% |
| Net Income | 81.90M -23.7% |
| EPS | 3.58 -22.8% |
| Shares Out | n/a |
| PE Ratio | 21.28 |
| Forward PE | 11.38 |
| Dividend | 1.98 (0.30%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | n/a |
| Average Volume | 161 |
| Open | n/a |
| Previous Close | 663.50 |
| Day's Range | n/a |
| 52-Week Range | 573.00 - 707.50 |
| Beta | 0.86 |
| RSI | 53.82 |
| Earnings Date | May 1, 2026 |
About LON:0O0N
Aktieselskabet Schouw & Co., an industrial conglomerate, manufactures feed for the fish and shrimp farming industries in Norway, Denmark, the United Kingdom, the rest of Europe, Chile, the United States, the rest of Americas, Asia, Oceania, and Africa. It operates in six segments: BioMar, GPV, HydraSpecma, Borg Automotive, Fibertex Personal Care, and Fibertex Nonwovens. The BioMar segment offers feed products for salmon, trout, shrimp, sea bass, and sea bream in the fish and shrimp farming industries. The GPV segment manufactures electronics, m... [Read more]
Financial Performance
In 2025, LON:0O0N's revenue was 34.13 billion, a decrease of -1.55% compared to the previous year's 34.67 billion. Earnings were 650.00 million, a decrease of -31.58%.
Financial numbers in DKK Financial StatementsNews
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q1 2026
Q1 2026 delivered EBITDA and EBT growth despite a 3% revenue decline, with strong operational execution and deleveraging. Segment performance was mixed, but guidance for the full year is maintained, and the BioMar IPO process has advanced.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q4 2025
Revenue and EBITDA declined slightly due to raw material and Forex headwinds, but cash flow hit a record high and leverage improved. Most segments delivered EBITDA growth, with strong guidance for 2026 and continued focus on capital discipline and efficiency.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q3 2025
Q3 saw a 4% revenue decline but a 5% EBITDA increase, driven by strong cost control and margin management. BioMar delivered record EBITDA despite biological headwinds, while other segments showed mixed results amid ongoing market uncertainties.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q2 2025
Revenue and EBITDA declined slightly year-over-year amid ongoing market volatility, but strong cash flow and reduced debt supported continued investment. BioMar, GPV, and HydraSpecma showed operational improvements, while Borg Automotive faced margin pressure and restructuring.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q1 2025
Q1 saw flat revenue and a 13% EBITDA decline, with strong cash flow and positive one-offs. Segment results were mixed, but full-year guidance is maintained, and BioMar's IPO evaluation is advancing. Market volatility and tariff risks persist.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q4 2024
Revenue declined 7% to DKK 34.7 billion in 2024, but EBITDA hit a record DKK 2.93 billion, with strong cash flow and reduced leverage. Segment results were mixed, with BioMar and BORG Automotive showing profit growth, while GPV and Fibertex Personal Care faced headwinds. 2025 guidance is cautiously optimistic.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q3 2024
Revenue and EBITDA declined year-over-year amid soft demand, inflation, and intense competition, but margins were largely maintained through cost reductions and efficiency gains. BioMar's strong performance and a potential IPO were key highlights, while guidance was narrowed across segments.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q2 2024
Q2 2024 saw a 5% revenue decline but an 11% EBITDA increase, driven by BioMar's strong margin uplift. Guidance for 2024 EBITDA was raised, despite softening demand and challenges in industrial segments, with profit protection and efficiency measures in place.